← Back to TCM Global · All articles

Ten Years of Ginsenoside Commercialization: The Long Game Decoded

2026-10-23

A Decade in One Timeline

The 21st Century Business Herald's deep dive on Giant Biogene's ginsenoside business reconstructs a decade-long journey:

| Year | Move |

|---|---|

| 2016 | First ginsenoside health food; 'Shengan' brand launches |

| 2019 | 'Xin'an' skincare brand extends the actives to topical use |

| 2022 | Joint incubation with beauty e-commerce operator Youke (Xin'an Bio) |

| 2023 | Three product lines: skincare, oral beauty, health food |

| Aug 2026 | Xin'an stores close; partnership restructures |

| Jun 2026 | Ginsenoside CK completes cosmetic new-ingredient registration |

| Oct 2026 | New brand '1'me Yiwuo' enters Li Jiaqi's livestream |

Ten years, multiple brand vehicles, one continuous technology bet.

The Three Lessons

1. Ingredients Outlive Brands

Every consumer brand in the timeline changed or closed. The ingredient technology — and now the registration and production scale — persisted and appreciated. Biotech companies should value their registered actives above their brand experiments.

2. Brand Operations Are a Different Craft

The Xin'an closure shows that pairing a biotech with a beauty e-commerce operator doesn't guarantee consumer success. Brand-building demands different muscles: narrative, channel management, community. Failure here doesn't invalidate the science.

3. Regulatory Milestones Compound

The CK registration is the timeline's turning point: it converts internal R&D into a legally recognized asset that any future brand — or licensing partner — can build on. Registrations appreciate; campaigns expire.

The Strategic Read

Giant Biogene's stated goal is replicating its recombinant collagen playbook — where a decade of ingredient science eventually produced Comfy, a multi-billion-yuan brand. Collagen now faces growth pressure (2026 H1 revenue down 6.3%), making the second engine urgent.

The honest caveat from the reporting: health-food and other businesses remain under 0.3% of revenue, and ginsenoside-specific sales aren't separately disclosed. The second engine is still warming up.

The Takeaway

Ten years is the real duration of an ingredient-to-brand journey. Most companies quit at year three. The lesson isn't persistence for its own sake — it's that regulatory registrations, production scale and technical data compound quietly while brands cycle.